136 related articles for article (PubMed ID: 8063043)
1. Randomized double-blind placebo-controlled trial to evaluate the effect of the ACTH4-9 analogue ORG 2766 in IDDM patients with neuropathy.
Bravenboer B; Hendrikse PH; Oey PL; van Huffelen AC; Groenhout C; Gispen WH; Erkelens DW
Diabetologia; 1994 Apr; 37(4):408-13. PubMed ID: 8063043
[TBL] [Abstract][Full Text] [Related]
2. Rationale for the use of the ACTH4-9 analogue ORG 2766 in the treatment of diabetic neuropathy.
Bravenboer B; Erkelens DW; Gispen WH
Neth J Med; 1992 Dec; 41(5-6):255-8. PubMed ID: 1337372
[No Abstract] [Full Text] [Related]
3. The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial.
van Gerven JM; Hovestadt A; Moll JW; Rodenburg CJ; Splinter TA; van Oosterom AT; Keizer L; Drogendijk TE; Groenhout CM; Vecht CJ
J Neurol; 1994 Jun; 241(7):432-5. PubMed ID: 7931444
[TBL] [Abstract][Full Text] [Related]
4. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer.
van der Hoop RG; Vecht CJ; van der Burg ME; Elderson A; Boogerd W; Heimans JJ; Vries EP; van Houwelingen JC; Jennekens FG; Gispen WH
N Engl J Med; 1990 Jan; 322(2):89-94. PubMed ID: 2152972
[TBL] [Abstract][Full Text] [Related]
5. Treatment of diabetic polyneuropathy with the neurotrophic peptide ORG 2766.
Valk GD; Kappelle AC; Tjon-A-Tsien AM; Bravenboer B; Bakker K; Michels RP; Groenhout CM; Bertelsmann FW
J Neurol; 1996 Mar; 243(3):257-63. PubMed ID: 8936356
[TBL] [Abstract][Full Text] [Related]
6. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer.
Roberts JA; Jenison EL; Kim K; Clarke-Pearson D; Langleben A
Gynecol Oncol; 1997 Nov; 67(2):172-7. PubMed ID: 9367703
[TBL] [Abstract][Full Text] [Related]
7. The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo.
Hovestadt A; van der Burg ME; Verbiest HB; van Putten WL; Vecht CJ
J Neurol; 1992 Mar; 239(3):143-6. PubMed ID: 1315383
[TBL] [Abstract][Full Text] [Related]
8. Effect of an ACTH(4-9) analogue on cisplatin neuropathy of longstanding duration: a phase II study.
Hilkens PH; van der Burg ME; Moll JW; van den Bent MJ; van Putten WL; Vecht CJ
Clin Neurol Neurosurg; 1995 May; 97(2):139-41. PubMed ID: 7656487
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effect of Org 2766 in treatment of peripheral neuropathy in streptozocin-induced diabetic rats.
Van der Zee CE; Van der Hoop RG; Gispen WH
Diabetes; 1989 Feb; 38(2):225-30. PubMed ID: 2536628
[TBL] [Abstract][Full Text] [Related]
10. Trial of an ACTH4-9 Analogue (ORG 2766) in children with intractable seizures.
Pentella K; Bachman DS; Sandman CA
Neuropediatrics; 1982 May; 13(2):59-62. PubMed ID: 6290927
[TBL] [Abstract][Full Text] [Related]
11. An ACTH-(4-9) analogue, Org 2766, improves recovery from acrylamide neuropathy in rats.
Sporel-Ozakat RE; Edwards PM; Van der Hoop RG; Gispen WH
Eur J Pharmacol; 1990 Sep; 186(2-3):181-7. PubMed ID: 1963145
[TBL] [Abstract][Full Text] [Related]
12. The MSH/ACTH analog ORG 2766 in anxiety disorders.
Den Boer JA; Westenberg HG; De Vries H
Peptides; 1992; 13(1):109-12. PubMed ID: 1320259
[TBL] [Abstract][Full Text] [Related]
13. Long-Acting C-Peptide and Neuropathy in Type 1 Diabetes: A 12-Month Clinical Trial.
Wahren J; Foyt H; Daniels M; Arezzo JC
Diabetes Care; 2016 Apr; 39(4):596-602. PubMed ID: 26884473
[TBL] [Abstract][Full Text] [Related]
14. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy.
Ekberg K; Brismar T; Johansson BL; Lindström P; Juntti-Berggren L; Norrby A; Berne C; Arnqvist HJ; Bolinder J; Wahren J
Diabetes Care; 2007 Jan; 30(1):71-6. PubMed ID: 17192336
[TBL] [Abstract][Full Text] [Related]
15. Does an ACTH derivative (Org 2766) prevent deterioration of EEG in Alzheimer's disease?
Partanen JV; Soininen H; Riekkinen PJ
Electroencephalogr Clin Neurophysiol; 1986 Jun; 63(6):547-51. PubMed ID: 2422004
[TBL] [Abstract][Full Text] [Related]
16. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial.
Malik RA; Williamson S; Abbott C; Carrington AL; Iqbal J; Schady W; Boulton AJ
Lancet; 1998 Dec 19-26; 352(9145):1978-81. PubMed ID: 9872248
[TBL] [Abstract][Full Text] [Related]
17. A controlled trial with ORG 2766, an ACTH-(4-9) analog, in 50 relatively able children with autism.
Buitelaar JK; Dekker ME; van Ree JM; van Engeland H
Eur Neuropsychopharmacol; 1996 Mar; 6(1):13-9. PubMed ID: 8866933
[TBL] [Abstract][Full Text] [Related]
18. [Effects of synthetic neuropeptides in psycho-organic brain syndrome. Results with ACTH4-10 and ACTH4-9-analog (author's transl)].
Schneider E; Jacobi P; van Riezen H; Voerman JW; Fischer PA
Pharmacopsychiatria; 1981 Sep; 14(5):155-9. PubMed ID: 6270708
[TBL] [Abstract][Full Text] [Related]
19. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.
Backonja M; Beydoun A; Edwards KR; Schwartz SL; Fonseca V; Hes M; LaMoreaux L; Garofalo E
JAMA; 1998 Dec; 280(21):1831-6. PubMed ID: 9846777
[TBL] [Abstract][Full Text] [Related]
20. A pilot study on the influence of a corticotropin (4-9) analogue on Vinca alkaloid-induced neuropathy.
van Kooten B; van Diemen HA; Groenhout KM; Huijgens PC; Ossenkoppele GJ; Nauta JJ; Heimans JJ
Arch Neurol; 1992 Oct; 49(10):1027-31. PubMed ID: 1329697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
